West Pharmaceutical Services Inc (WST) Receives Equal-Weight Rating
Morgan Stanley initiates coverage on West Pharmaceutical Services Inc (WST) with an Equal-Weight rating.
West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,600 full-time employees. The firm operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for West Pharmaceutical Services Inc.
Last Updated: Nov 25, 2025, 11:12 PM · Source: Finnhub.io
Morgan Stanley initiates coverage on West Pharmaceutical Services Inc (WST) with an Equal-Weight rating.
Rothschild & Co initiates coverage on West Pharmaceutical Services Inc with a Buy rating.